Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

afatinib

GIOTRIF

afatinib (GIOTRIF) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01XE13
US status approved
Patents linked 18
Pipeline programs 8
News articles 0
Drug details — afatinib
US status
approved
Class
Antineoplastic and immunomodulating agents (L01)
Route
ORAL
Patents
18
Programs
8
Data quality
0.84
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

afatinib (GIOTRIF) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN afatinib
Brand GIOTRIF
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
Route ORAL
Formulation TABLET
ATC code L01XE13
Originator Boehringer Ingelheim Pty Ltd

Mechanism of action

Epidermal growth factor receptor erbB1 inhibitor

Approval history

Authority Status Date
FDA approved —
EMA approved —
TGA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Afatinib Phase 3 · Boehringer Ingelheim · Head and Neck Neoplasms
  2. FURMO-006 Phase 3 · ArriVent BioPharma · Advanced or Metastatic Non-Small-Cell Lung Cancer With Epide
  3. Afatinib and Paclitaxel Phase 2 · United Therapeutics Europe · Esophageal Cancer
  4. Afatinib once daily (OD) Phase 2 · Boehringer Ingelheim · Breast Neoplasms
  5. BI-754091 plus afatinib Phase 2 · Chinese Academy of · Esophageal Squamous Cell Carcinoma (ESCC)
  6. IRSSP-001 Phase 2 · George Institute for · Patients diagnosed with unresectable and / or metastatic loc
  7. PB-2018-V12 Phase 1 · Chongqing Precision Biotech · Non-small Cell Lung Cancer
  8. Afatinib Approved · Boehringer Ingelheim · Carcinoma, Non-Small-Cell Lung

Related & competitor drugs

Browse all drugs
  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Related patents

Browse patents Boehringer Ingelheim Pty Ltd patent hub

  1. WO 2026114918

    DÉRIVÉS DE 2-AMINO-3-CYANO THIOPHÈNE ANNELÉS SPIROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS POUR LE TRAITEMENT DU CANCER

    Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026114957

    DÉRIVÉS DE THIOPHÈNE 2-AMINO-3-CYANO SPIROCYCLIQUES ANNELÉS EN TANT QUE DÉGRADEURS DE KRAS POUR LE TRAITEMENT DU CANCER

    Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2026109631

    UTILISATION DE PROTÉINES ENGAGEANT LES LYMPHOCYTES T DANS LE TRAITEMENT DU CANCER

    Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 20260146050

    KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES

    Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2026099754

    MÉTHODE DE RÉDUCTION DE L'EXCRÉTION VIRALE, DE COLONISATION DE TISSU ET DE DÉPLÉTION LYMPHOÏDE PROVOQUÉES PAR OU ASSOCIÉES À UNE INFECTION PAR PCV2

    Expires Thu May 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 20260116870

    NOVEL NAV 1.1 POTENTIATORS

    Expires Wed Apr 25 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2026082715

    DÉPLÉTION DES MACROPHAGES ET VIRUS DE LA STOMATITE VÉSICULAIRE POUR LE TRAITEMENT DU CANCER

    Expires Wed Apr 18 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 20260096994

    SOLID DISPERSIONS HAVING STABILIZED EMULSION PARTICLES

    Expires Wed Apr 04 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2026046899

    PYRAZOLO[5,1-f][1,2,4]TRIAZIN-4-ONES EN TANT QU'INHIBITEURS DE NOX4

    Expires Wed Feb 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2026041123

    VACCINS À VECTEUR DEV CONTRE LA GRIPPE AVIAIRE

    Expires Wed Feb 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2026013162

    VECTEUR VACCINAL DU VIRUS HERPÈS DU DINDON POUR LE TRAITEMENT ET LA PRÉVENTION D'INFECTIONS PROVOQUÉES PAR LE VIRUS DE LA GRIPPE AVIAIRE CHEZ DES DINDONS

    Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 20260015393

    NOVEL NMU RECEPTOR 2 AGONISTS

    Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2026007886

    COMPOSITION IMMUNOGÈNE CONTRE LE SOUS-TYPE H7 DU VIRUS DE LA GRIPPE AVIAIRE

    Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2026007889

    COMPOSITION IMMUNOGÈNE CONTRE LE SOUS-TYPE H7 ET LE SOUS-TYPE H5 DU VIRUS DE LA GRIPPE AVIAIRE

    Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. WO 2026007883

    COMPOSITION IMMUNOGÈNE CONTRE LE SOUS-TYPE H7 DU VIRUS DE LA GRIPPE AVIAIRE

    Expires Wed Jan 03 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 2025382344

    Soluble GLP1/GIP/NPY2 Receptor Triple Agonists

    Expires Wed Dec 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. WO 2025257278

    SÉQUENCES IMMUNOGÈNES

    Expires Wed Dec 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. AU 2007283667

    Genes and proteins of Brachyspira hyodysenteriae and uses thereof

    Expires Wed Feb 09 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is afatinib?

afatinib (GIOTRIF) is a epidermal growth factor receptor erbb1 inhibitor. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for afatinib?

GIOTRIF is a marketed brand name for afatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of afatinib?

afatinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.